Clinical Support

In a clinical study, women taking a daily oral dose of EQUELLE (containing 10mg S-equol per dose) reduced their frequency of hot flashes by 58.7% after 12 weeks of treatment (n=77), significantly (p<0.01) more than the 34.5% reduction experienced in women receiving a placebo (n=83).1

Women receiving S-equol 10 mg/day (n=77) had significant improvements in the severity of their neck or shoulder muscle stiffness compared to placebo (n=83).4

Proven Safety Profile in Menopausal Women

In clinical studies of Equelle, there were no major adverse events reported.1,4

The active ingredient S-equol is affirmed safe in both food and drug supplements. S-equol has 13-fold preference for binding to ERβ rather than for estrogen receptor α (ERα)5, which is present in the uterus and breast. Studies involving postmenopausal women who consumed the supplement containing S-equol have not observed any safety problems, including analysis of breast and uterine tissues and of hormone levels.1,4

In a clinical study, women taking a daily oral dose of EQUELLE (containing 10mg S-equol per dose) reduced their frequency of hot flashes by 58.7% after 12 weeks of treatment (n=77), significantly (p<0.01) more than the 34.5% reduction experienced in women receiving a placebo (n=83).1

The active ingredient ingredient in EQUELLE is S-equol, a naturally derived compound of the soy isoflavone daidzein that is produced through the fermentation of soy germ. This molecule naturally occurs in the gut of some women after eating soy, and may result in fewer hot flashes† for menopausal women. It is structurally similar to estrogen, and mimics some, but not all, estrogenic activities.

S-equol is a metabolite of the soy isoflavone daidzein. S-equol is produced by intestinal bacteria in some, but not in all, humans after soy consumption. The ability of S-equol to play a role in the treatment of estrogen-mediated conditions was first proposed in 1984.6 Studies of postmenopausal women documented that those women who can produce equol after consuming soy had milder menopause symptoms than those who were unable to produce equol.7,8S-equol is exclusively a product of the bacterial transformation of daidzein. The molecular and physical structure of S-equol is similar to that of 17-estradiol,9 also referred to as estrogen, and mimics some, but not all, estrogenic activities.

As EQUELLE contains a soy-based ingredient, individuals who are allergic to soy should not take this product. In addition, women who are pregnant, nursing or trying to become pregnant should not use EQUELLE as the product has not been tested in these groups.

You do not need a prescription for EQUELLE, however, patients should consult with their physician or healthcare professional before taking EQUELLE, especially if they are already taking medications or other supplements.